Abstract 3059: Discovery of BET family proteins as cancer targets using phenotypic-based profiling and affinity capture mass spectrometry
Scott E. Warder(AbbVie (United States)), Yu Shen(University of Florida), Heather M. Davis(AbbVie (United States)), Sanjay C. Panchal(AbbVie (United States)), Hua Tang(Guangdong University of Technology), Fritz G. Buchanan(AbbVie (United States)), Melanie J. Patterson(DePaul University), Sadiya N. Addo(AbbVie (United States)), Dong Cheng(AbbVie (United States)), Chang H. Park(AbbVie (United States)), David J. Calderwood(AbbVie (United States)), Shaun M. McLoughlin(AbbVie (United States)), Andrew M. Petros(Abbott Fund), M. Shannon Duggan(AbbVie (United States)), Paul L. Richardson, Steven W. Elmore(AbbVie (United States)), Chaohong Sun(AbbVie (United States)), Denise M. Wilcox(AbbVie (United States)), Terkel Hansen(AbbVie (United States))
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k